These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 6420165)
1. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction. Oltmanns D; Pottage A; Endell W Eur J Clin Pharmacol; 1983; 25(6):787-90. PubMed ID: 6420165 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. Wiegers U; Hanrath P; Kuck KH; Pottage A; Graffner C; Augustin J; Runge M Eur J Clin Pharmacol; 1983; 24(4):503-7. PubMed ID: 6407848 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tocainide in patients with severe renal failure. Braun J; Sörgel F; Engelmaier F; Gluth WP; Gessler U Eur J Clin Pharmacol; 1985; 28(6):665-70. PubMed ID: 3933983 [TBL] [Abstract][Full Text] [Related]
4. Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects. McErlane KM; Axelson J; Vaughan R; Kerr CR; Price JD; Igwemezie L; Pillai G Eur J Clin Pharmacol; 1990; 39(4):373-6. PubMed ID: 2127569 [TBL] [Abstract][Full Text] [Related]
5. Alteration of the kinetics of tocainide in combined hepatic and renal insufficiency. Endell W; Oltmanns D; Pottage T Methods Find Exp Clin Pharmacol; 1983 Oct; 5(8):589-90. PubMed ID: 6420626 [No Abstract] [Full Text] [Related]
6. Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. MacMahon B; Bakshi M; Branagan P; Kelly JG; Walsh MJ Br J Clin Pharmacol; 1985 Apr; 19(4):429-34. PubMed ID: 3922392 [TBL] [Abstract][Full Text] [Related]
7. Stereoselective disposition of RS-tocainide in man. Hoffmann KJ; Renberg L; Bäärnhielm C Eur J Drug Metab Pharmacokinet; 1984; 9(3):215-22. PubMed ID: 6440790 [TBL] [Abstract][Full Text] [Related]
8. The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction. Upward JW; Holt D; Emery P; Akhras F; Jackson G Eur J Clin Pharmacol; 1983; 25(5):589-94. PubMed ID: 6420162 [TBL] [Abstract][Full Text] [Related]
9. Stereospecific salivary excretion of tocainide enantiomers in man. Pillai GK; Axelson JE; Kerr CR; McErlane KM Res Commun Chem Pathol Pharmacol; 1984 Feb; 43(2):209-21. PubMed ID: 6424192 [TBL] [Abstract][Full Text] [Related]
10. On the kinetics and dynamics of tocainide and its metabolites. Ronfeld RA; Wolshin EM; Block AJ Clin Pharmacol Ther; 1982 Mar; 31(3):384-92. PubMed ID: 6800678 [TBL] [Abstract][Full Text] [Related]
11. Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. Hoffmann KJ; Renberg L; Gyllenhaal O Biopharm Drug Dispos; 1990; 11(4):351-63. PubMed ID: 2111189 [TBL] [Abstract][Full Text] [Related]
12. Tocainide. A review of its pharmacological properties and therapeutic efficacy. Holmes B; Brogden RN; Heel RC; Speight TM; Avery GS Drugs; 1983 Aug; 26(2):93-123. PubMed ID: 6411445 [TBL] [Abstract][Full Text] [Related]
13. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis AM; Kates RE Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721 [TBL] [Abstract][Full Text] [Related]